INTRODUCTION
Coagulation factor VIII (FVIII) plays a fundamental role in the amplification and propagation of the coagulation cascade, enabling the thrombin burst during haemostasis. High levels of FVIII are well known to be an important risk factor for venous thrombosis [1] [2] [3] and have been associated also with an increased risk of arterial thrombosis and coronary artery disease (CAD) [4] [5] [6] . As consistent counterpart, haemophilia patients with low levels of FVIII present a lower mortality due to ischaemic heart disease than the general population [7] [8] [9] .
Although the heritability of FVIII plasma levels is high (near 40-60%) [10, 11] , variations of FVIII gene explain only a minor proportion of this broad variance [12] [13] [14] . Up to now, SNPs at only two other genes, the ABO blood-group locus and the low density lipoprotein receptor-related protein 1 (LRP1), have been demonstrated to contribute to the modulation of FVIII plasma levels [10, 15, 16] .
The ABO blood group determinants have been proposed to affect, through different glycosylation patterns, the processing and/or the clearance of von Willebrand factor (vWF), which in turn binds and stabilizes FVIII [17, 18] . The multifunctional endocytic receptor LRP1 mediates cellular uptake and subsequent degradation of FVIII [19] [20] [21] and SNPs at this locus have been associated with FVIII activity (FVIII:c) and the risk of venous thromboembolism [15, 16] . Recently, also the LDL receptor (LDLR) has been proposed to contribute to the regulation of FVIII plasma levels. Indeed, FVIII has been demonstrated to be a ligand of LDLR, and in mice models LDLR cooperates with LRP1 in regulating plasma levels of FVIII in vivo, suggesting a previously unrecognized link between LDLR and haemostasis [22] .
Few molecules have been recognized to play a pivotal role in atherosclerotic disease like LDLR.
The cornerstone work of the Nobel prize-winners Goldstein and Brown has clearly demonstrated the importance of LDLR in cholesterol homeostasis and, consequently, in the processes that lead to atherosclerotic cardiovascular disease [23] . This is further emphasized by the LDLR mutations leading to familial hypercholesterolemia, a well known cause of accelerated atherosclerosis [24] .
Moreover, recent genome-wide association studies (GWAS) have highlighted that common variations at the LDLR locus are strongly associated with proatherogenic lipid profile and with CAD [25, 26] .
Among the several common genetic variants described at LDLR locus, the rs2228671 C/T appears to have the strongest association with LDL-cholesterol levels across multiple European populations, with the T allele being associated to decreased LDL-cholesterol levels and, consistently, to a decreased risk of CAD [27] . The rs688 C/T in exon 12 has been recently shown to alter splicing efficiency, with the T allele being associated to increased total and LDL-cholesterol levels in preFor personal use only. on October 28, 2017. by guest www.bloodjournal.org From 4 menopausal women [28] . Finally, the rs1122608 G/T at the 19p13 locus within SMARC4A intron 30 and adjacent to LDLR gene has been reproducibly associated with high LDL cholesterol levels (G allele) and with an increased risk of myocardial infarction (MI) by means of GWAS [25, 26] .
Remarkably, these 3 SNPs have been shown to be not in significant linkage disequilibrium ( Figure   1 ), being thus highly informative for SMARCA4-LDLR gene locus.
The aim of this study was to evaluate the possible associations of these SNPs with FVIII:c levels, as well as with CAD. With such aim in mind we selected a subgroup of subjects within the frame of the angiographically controlled Verona Heart Study (VHS) [29, 30] .
SUBJECTS AND METHODS

Study population
This study was performed within the framework of the Verona Heart Study (VHS), a regional survey aimed to search for new risk factors for CAD in subjects with angiographic documentation of their coronary vessels. Details about enrolment criteria have been described elsewhere [29, 30] . In brief, adult patients of both sexes who were recruited consecutively from those referred to the Institutes of Internal Medicine and to the Institute of Cardiovascular Surgery of the University of Verona in Italy between May 1996 and June 2000 and undergoing to a coronary angiography examination (n=1,122). A total of 983 subjects, who were not taking anticoagulant drugs and for whom rs688 polymorphisms and FVIII:c data were available, were included in the present study.
FVIII:c was measured at time of enrolment (details about study design are summarized in Figure 2 ). Two-hundred ninety one subjects had completely normal coronary arteries, being submitted to coronary angiography for reasons other than CAD, mainly valvular heart disease (CAD-free group), and serve as controls. These subjects were also required to have neither history nor clinical or instrumental evidence of atherosclerosis in vascular districts beyond the coronary bed and none was on anti-platelet drugs. Six-hundred ninety two subjects had angiographically proven CAD (the majority of them being candidates for coronary artery bypass grafting) with at least one of major epicardial coronary arteries (left anterior descending, circumflex, and right) affected with ≥ 1 significant stenosis (≥50% lumen reduction). Most of CAD patients were taking anti-platelet drugs (95.2%). According to the hypothesis to be tested, subjects with non-advanced CAD (i.e. coronary stenosis <50%) were not included in the study. The angiograms were assessed by cardiologists who were unaware that the patients were to be included in the study.
All participants came from the same geographical area (Northern Italy), with a similar socioeconomic background. At the time of blood sampling, a complete clinical history was collected, including the assessment of cardiovascular risk factors such as obesity, smoking, hypertension and 5 diabetes, as well as data about drug therapies (e.g. lipid-lowering therapies). The study was approved by the Ethic Committee of our Institution (Azienda Ospedaliera, Verona). An informed consent was obtained from all the participants after a full explanation of the study in accordance with the Declaration of Helsinki.
Biochemical analysis and coagulation factors activity assays.
Samples of venous blood were drawn from each subject, after an overnight fast, at time of enrolment before coronary angiography. Serum lipids, as well as other CAD risk factors, including hs-CRP, were determined as previously described 
SNPs and Genotyping
Three SNPs tagging the SMARCA4-LDLR gene locus were selected, i.e.rs688, rs2228671, and rs1122608. The 3 selected SNPs tag most variability of the SMARCA4-LDLR region from the HapMap project (Figure 1 ). Genomic DNA was prepared from whole blood samples by phenolchloroform extraction. For rs688 and rs2228671 polymorphisms genotyping was performed as following: briefly, the rs688 polymorphism (LDLR 1773C/T) was detected by PCR using the Considering that the original studies in mice supported a cooperation of LDLR with LRP1 in modulating plasma levels of FVIII [22] , we explored the possibility of an interaction between genetic variants within the two genes. Thus, our study population was genotyped also for the LRP1 
7
RESULTS
FVIII:c levels and risk of CAD
The general characteristics of the study population, divided into CAD-free and CAD groups, are summarized in Table 1 . As expected, the classical risk factors for atherosclerosis were more frequent in subjects with CAD than in those without CAD.
CAD patients had higher FVIII:c levels than CAD-free subjects (172 ± 55 versus 149 ± 47 IU/dL; P < 0.001). According to the tertile distribution of FVIII:c in the whole population, the proportion of CAD patients increased progressively from the lowest to the highest tertile (59.9%, 69.2%, and 81.9%, respectively; P < 0.001 by χ 2 for trend analysis). Considering subjects with FVIII:c in the 
Genotype/fenotype correlations for SNPs at LDLR/SMARCA4 loci.
The genotype distribution for each SNP was consistent with Hardy-Weinberg equilibrium both in cases and in controls (Table 1) . Moreover, the three SNPs tested were not in linkage disequilibrium
) and a similar LD pattern was also observed in our study population (Supplemental Table 1 ).
rs688 -LDLR exon 12.
The carriers of the rs688 T allele had higher FVIII:c levels than CChomozygotes ( Table 2) . In a regression model adjusted for the main determinants of FVIII:c variability, the carriership of T allele remained a significant predictor of FVIII:c (beta coefficient 7.49; P = 0.037 - Table 3 ). On the other hand, no significant association was found with lipid variables, both in the whole study population and in subjects without lipid-lowering therapies (Table 4) . Consistently with the high FVIII:c levels, the carriers of rs688 T allele were more represented among CAD patients ( estimated GFR, and hs-CRP).
rs2228671 -LDLR exon 2.
The carriers of the rs2228671 T allele presented also higher FVIII:c levels ( Table 2) , and in a regression model adjusted for the main determinants of FVIII:c variability, the carriership of T allele remained a significant predictor of FVIII activity (beta coefficient 7.43; P = 0.048 - Table 3 ). On the other hand, carriership of the T allele was associated with a more favourable lipid profile, particularly evident in subjects without lipid-lowering therapies, characterized by lower plasma concentrations of total and LDL cholesterol, and a lower total to HDL cholesterol ratio ( Table 4) . Carriers of the rs2228671 T allele did not present a different risk of CAD (Table 1) .
rs1122608 -SMARCA4 intron 30. The rs1122608 genotype was not associated with FVIII:c levels ( Table 2) , while the carriers of the rs1122608 T allele were characterized by a favourable lipid profile, particularly evident in subjects without lipid-lowering therapies, with lower triglyceride plasma concentrations and lower total to HDL cholesterol ratio (Table 4) . Consistently with the favourable lipid profile, the carriers of rs1122608 T allele were less represented among CAD patients (Table 1) , with a reduced OR for CAD (0.64 with 95%CI 0.48-0.85 by univariate analysis).
As regards to the association with CAD, the LDLR and SMARCA4 SNPs were included in a multiple logistic regression model adjusted for all the traditional cardiovascular risk factors, including lipid profile. Only the carriership of rs688 T allele remained an independent risk of CAD (OR 1.67 with 95%CI 1.10-2.54), while the rs1122608 genotype lost its statistically significant association (OR 0.82 with 95%CI 0.54-1.25).
Analysis of single nucleotide polymorphisms in the LDLR locus (rs688, rs2228671) for FII:c and FV:c levels.
To evaluate if genotype effect of rs688 and rs2228671 was specific for FVIII or more broad on other coagulation factors, also FII:c and FV:c levels were assessed. Remarkably, no association was found between the above mentioned polymorphisms and levels of FII:c or FV:c (Supplemental Table 2 ).
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Analysis of LRP1 -25C/G polymorphism
The LRP1 -25C/G polymorphism was not associated with either CAD (Table 5A) or FVIII:c levels or lipid parameters (Table 5B in the whole study population and Supplemental Table 3 in subjects without lipid-lowering therapy). The homozygotes for the G allele showed a trend toward low concentrations of total and LDL cholesterol and high levels of FVIII:c (Table 5B) . However, the low number of the GG-homozygotes (n=16) does not allow to draw any firm conclusion.
Remarkably, both LDLR SNPs (rs688 and rs2228671) remained significant predictors of FVIII:c variability after the inclusion of LRP1 -25 C/G polymorphism in a sex-and age-adjusted regression 
Haplotype analysis
We then performed an haplotype analysis considering the 3 SMARCA4-LDLR SNPs (rs1122608, rs2228671, and rs688). The two most frequent haplotypes in the whole population were G-C-C, and G-C-T (Table 6 ). In sex-and age-adjusted generalized model regressions of traits, the haplotypes were significantly associated with both FVIII:c levels and lipid plasma concentrations, i.e. total and LDL cholesterol, and total to HDL cholesterol ratio. Consistently with such results, haplotypes were also associated with a different prevalence of CAD (Table 6 ). In particular, the G-C-T haplotype, characterized by the high FVIII:c-associated rs688 T allele, was more frequent in CAD than in CAD-free subjects (36.6% versus 31.6%, respectively), while the T-C-C haplotype, characterized by the favourable lipid profile-associated rs1122608 T allele, was less frequent in CAD than in CAD-free subjects (14.1% versus 18.5%, respectively). Subjects with G-C-T haplotype carried a greater risk of CAD than subjects with T-C-C haplotype (OR: 1.59 with 95%CI 1.17-2.18; P=0.003 in a sex-and age-adjusted model and P=0.021 after 1000 permutations by Monte Carlo method; Table 6 ).
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DISCUSSION
In this study we demonstrate for the first time that SNPs at the LDLR locus may contribute to the variability of FVIII:c. Moreover, these SNPs were differently associated with CAD, consistently with FVIII:c levels and independently from lipid profile. Thus, the LDLR locus may have pleiotropic influences on either plasma lipid or coagulation factor concentrations, that in turn may modulate the risk of CAD.
To put our results into perspective, we propose the following considerations.
FVIII:c and CAD risk.
FVIII is well known to play a pivotal role in the coagulation cascade. Elevated FVIII levels are The rs688 is a synonymous SNP located within LDLR exon 12 and has been originally discovered in 1988 [39] . This genetic variant is quite common among Caucasian populations, being the frequency of T allele carriers near to 65%. Previous studied have related rs688 with lipid profile [28, 40] , but to the best of our knowledge no association with cardiovascular disease has been described. Zhu and colleagues proposed a functional role for this SNP through neutralization of an exon splicing enhancer [28] , and independently from the splicing factor SFRS13A [41] . In this way, the T allele has been associated with an increased proportion of LDLR isoforms lacking the transmembrane domain. The "truncated" (soluble) LDLR has been proposed to act by binding LDL and inhibiting its uptake by the normal, transmembrane LDLRs. According to this hypothesis, the T allele was associated with increased total and LDL cholesterol in pre-menopausal females of the Framingham Offspring Study, but not in males or post-menopausal females, suggesting a possible sex-and age-specific effect [28] . In our study we did not detect any significant association between rs688 and lipid profile. Our study population was represented mainly by males, and almost all the 11 females were post-menopausal. Thus, our results are substantially in agreement with those by Zhu and colleagues. On the other hand, we found that rs688 was an independent predictor of FVIII:c and, consistently with the high FVIII:c levels, the T allele was associated to an increased risk of CAD. Moreover, the association of rs688 with CAD risk remained unchanged after adjustment for plasma lipids by logistic regression, but was no longer statistically significant after inclusion of FVIII:c levels. Our results strongly support the hypothesis of an alternative pathway linking LDLR to the cardiovascular risk regardless of the lipid profile, i.e. through modulation of FVIII:c levels (Supplemental Figure 1A) . In a previous work, Bovenschen and colleagues [22] unknown, but it could be in linkage disequilibrium with pathogenic SNP within the adjacent LDLR, being associated with LDL cholesterol levels [25] . Our results support this view, since the carriers of T allele presented a favourable lipid profile and a reduced risk of CAD, while the adjustment for plasma lipids by logistic regression abolished the significant association between rs1122608 and CAD. Again, this suggests that the link between rs1122608 and CAD is through changes in plasma lipids (Supplemental Figure 1B) and that, unlike the rs688, there is no additional pathway contributing to the risk profile.
rs2228671 and the balance of FVIII and lipid phenotypes on CAD risk.
The rs2228671 polymorphism is located within LDLR exon 2 in the third position of a triplet coding for cysteine. Similarly to the other LDLR intragenic SNP rs688, it does not result in an Intriguingly, the rs2228671-related effects on the lipid and coagulation phenotypes were theoretically contrasting as regards to the susceptibility to CAD. Indeed, the minor T allele was associated with both high FVIII:c and low LDL-cholesterol, thus we were tempting to speculate that the proatherogenic action of high FVIII:c could be counterbalanced by the atheroprotective role of low LDL-cholesterol. According to the putative net sum of effects on the final phenotype, i.e. the risk of CAD was unchanged in our population (Supplemental Figure 1C ).
Haplotype analysis: SMARCA4-LDLR haplotypes as determinant of plasma lipids, FVIII:c, and CAD risk.
The 3 SNPs at LDRL locus were not in linkage disequilibrium, allowing to perform an informative haplotype analysis of this locus. Consistently with the SNPs analyses, the SMARCA4-LDLR haplotypes were associated with both plasma lipids, FVIII:c levels, and CAD. In this sense, the difference in risk of CAD between the haplotypes G-C-T and T-C-C (rs1122608-rs2228671-rs688) is paradigmatic. The G-C-T, including the rs688 T allele, showed consistently high FVIII:c levels and was more represented in CAD patients. The T-C-C, including the rs1122608 T allele, showed consistently low LDL cholesterol levels and was more represented in CAD-free subjects. The low frequencies of the other haplotypes (T-T-T and T-T-C), characterized by alleles with potentially either harmful or favourable effects, does not allow to draw any further conclusion.
LRP1 -25C/G polymorphism did not significantly interact with LDLR SNPs in determining FVIII:c.
Since previous work on LDLR knock-out mice suggested a cooperation between LDLR and LRP1 in modulating FVIII:c levels [22] , we also genotyped our study population for the known -25C/G polymorphism in the LRP1 promoter [15] . However, this SNP was not significantly associated to either FVIII:c levels or CAD, and did not show any significant interactions with LDLR polymorphisms. After inclusion of the -25C/G LRP1 polymorphism in the regression model, both 13 rs688 and rs2228671 remained significant predictors of FVIII:c variability, further supporting an independent association of these LDLR polymorphisms with FVIII:c in humans.
Study limitations and strengths.
Our study has some limitations that need to be taken in account. These are mainly related to the case-control design, as well as the relatively low and unbalanced sample size. Nevertheless, it was sufficiently powered for both FVIII:c and genotype analysis (>85% by Altman nomogram).
Similarly, the angiographic definition of cases and controls represents a strength of our work, preventing from enrolling in control group subjects with asymptomatic, but still significant CAD.
With respect to the association between FVIII:c and CAD, the lack of available data on vWF represents a potential limitation. vWF carries and stabilizes FVIII in the circulation, and plays an important role in haemostasis by facilitating platelet activation and thrombus formation. Therefore, it has been argued that FVIII involvement in arterial thrombosis may reflect the interaction with vWF [34] . On the other hand, epidemiological studies have shown that the risk of venous thrombosis in individuals with elevated FVIII:C levels is independent of vWF levels [1, 42] , and the Atherosclerosis Risk and Communities (ARIC) investigators recently reported an almost identical association of FVIII:c and vWF with CAD events during long-term follow-up (average 12.4 years) [43] . Anyhow, since the molecular interaction between LDLR appears limited to FVIII and not to vWF [22] , it is plausible that the lack of vWF data did not weaken the cornerstone concept of our hypothesis, i.e. a FVIII-related pathway linking LDLR and CAD beyond lipoprotein metabolism.
Moreover, it is worthy to note that our analysis about FVIII:c determinants has been adjusted also for ABO blood group, that in turn has been proposed to affect FVIII:c levels by means of differential glycosylation and thus metabolism/catabolism of vWF [17, 18] . [44] [45] [46] , suggesting that a prolongation of FVIII lifetime may indeed result from mutations of residues critical for the interaction of FVIII with both LRP and LDLR [44] .
Conclusions and perspectives.
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In our study three SNPs at the 19p3 locus (SMARCA4-LDLR) were associated with both plasma lipid concentrations and FVIII:c levels, and -consistently with these intermediate phenotypeswith CAD risk. In particular, the results on rs688 suggest that a LDLR polymorphism may be associated with cardiovascular disease beyond the lipoprotein metabolism pathway, probably through a FVIII-related mechanism. To the best of our knowledge, our results are the first supporting the hypothesis of a role of LDLR in regulating FVIII plasma levels in humans, accordingly with the original data by Bovenschen and colleagues in vitro and in mice models [22] .
Our results also provide a few light in the still obscure field of the genetic determinants of FVIII, and further emphasize the potential importance of FVIII-related pathways in atherosclerotic disease.
The functional dynamism and the potential adaptability to new biochemical properties are increasingly recognized as a pivotal capacity of several molecules acting in biological pathways [47] , and receptors are particularly suitable to multiple binding functions. Our results suggest that the biochemical properties and abilities of LDLR are not limited to lipoprotein metabolism, but may be extended to haemostatic balance. Remarkably, patients with familial hypercholesterolemia have been shown to present a net procoagulant pattern also independently of plasma LDL cholesterol level [48] and could be an adequate population model addressing the role of an extremely low expression of LDLR in modulating FVIII:c levels in further studies. Moreover, by proposing new functional capacities of LDLR activity, our results may offer new interpretation for therapeutic implications. Interestingly, a recent clinical trial has showed that the lipid-lowering therapy with rosuvastatin was associated with a decreased risk of venous thrombosis [49] . This effect was not completely explained by the well-known actions of statins, e.g. lipid-lowering and antiinflammatory. On the other hand, considering that statins are known to increase the expression of LDLR, the possible ensuing increased clearance of FVIII:c may represent an adjunctive mechanism for decreasing the thrombotic risk. However, it should be noted that no clear statement of causality can be drawn from data reflecting a risk association, as well as that our results ask for validation in other population studies, particularly with prospective design. Further studies are needed in this direction addressing the intriguing prospect of alternative pathways linking LDLR and cardiovascular risk beyond lipoprotein metabolism.
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CG (n=174)
163 ± 52 0.295 Table 6 : Distribution of SMARC4-LDLR haplotypes (on the basis of rs1122608, rs2228671, and rs688 polymorphisms) in the whole population and in subjects with or without coronary artery disease (CAD) and associations with FVIII:c, total and LDL cholesterol levels, and total to HDL cholesterol ratio. Alleles associated with high FVIII:c levels at SNPs analysis are marked by a red circle, while alleles associated with a favourable lipid profile are marked by a green circle. Haplotypes present in < 10 subjects were excluded from the analysis. Data about total and LDLcholesterol were analysed in the subgroup of patients without lipid-lowering therapies (n=693). 
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